Good morning investors, and welcome to my very first newsletter on Substack. I have been motivated to start this weekly transmission for a few reasons.
As concerns about banking contagion escalate, UBS is considering a possible acquisition of Credit Suisse.
Sources have reported that UBS AG (UBSG.S) is considering the acquisition of Credit Suisse (CSGN.S), its struggling Swiss counterpart, in an effort to prevent the ongoing crisis at the bank
Credit Suisse sued by U.S shareholders
Credit Suisse’s recent troubles have led to its first lawsuit by US investors, who claim that the bank exaggerated its financial prospects to shareholders.
Bank stocks are experiencing a decline as Credit Suisse’s actions trigger concerns of a new crisis.
As Credit Suisse’s largest shareholder rules out injecting additional funds into the troubled lender, concerns over the banking sector have deepened, leading to a decline in the stock markets.
Poolbeg Pharma PLC (AIM:POLB) POLB 001 patent portfolio strengthened
POLB 001 patent portfolio strengthened through granting of US patent
Poolbeg Pharma Plc (AIM:POLB) Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Vela Technologies (AIM:VELA) Quarterly Investment Update
The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 31 December 2022.
Poolbeg Pharma PLC (AIM:POLB) Strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Poolbeg Pharma PLC (AIM:POLB) Positive Initial Data Analysis in POLB 001 Trial
Early data readout indicates a successful LPS human challenge trial
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent update
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Vela Technologies (AIM:VELA) Update re. St George Street Capital COVID-19 trial
The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that St George Street Capital Ltd (“SGSC”), has today announced the